Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Debt / NOTE 3.250% 7/0
-
Market price (% of par)
-
100.49%
-
Total 13F principal
-
$9,719,000
-
Principal change
-
-$87,227,832
-
Total reported market value
-
$10,109,022
-
Number of holders
-
4
-
Value change
-
-$86,491,702
-
Number of buys
-
1
-
Number of sells
-
15
Institutional Holders of INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 as of Q2 2023
As of 30 Jun 2023,
INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 was held by
4 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$9,719,000
in principal (par value) of the bond.
The largest 4 bondholders included
OAKTREE CAPITAL MANAGEMENT LP, UBS ASSET MANAGEMENT AMERICAS INC, Congress Wealth Management LLC / DE /, and WEDBUSH SECURITIES INC.
This page lists
4
institutional bondholders reporting positions
for the Q2 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.